Holguin deploys greater vector control
- Written by Redacción ¡ahora!
- Category: Health
- Hits: 1204
After receiving the authorization of the Center for State Control of Medicines, Equipment and Medical Devices (Cecmed) and the approval of the Ministry of Public Health, a phase II-III clinical trial began at the Institute of Hematology and Immunology, aimed at evaluating the safety, immunogenicity and efficacy of a new version of the Cuban anti-pneumococcal vaccine Quimio-Vio, in adults from 50 to 74 years of age.
Topics related to the therapeutic modalities of Natural and Traditional Medicine (MNT) approved in Cuba and research developed to contribute to raising the quality of life of the population, occupied the attention of professionals attending the IX Scientific Conference of the Chapter of Bioenergetic and Natural Medicine, held on Wednesday in the city of Holguín.